The nature of biopharma M&A changed dramatically in a year. After a period with no deals over $5 billion, there are now seven or eight such transactions, reflecting a pivot by large pharma to acquire de-risked assets with large market potential to offset looming patent expirations.

The complex litigation around COVID vaccine technologies highlights a fundamental tension. Scientific breakthroughs often result from decades of collaborative work, but commercial reality forces this messy history into neat corporate boxes for IP ownership, inevitably leading to high-stakes legal battles over who deserves credit and compensation.

Contrary to the focus on large upfront payments, a smarter partnership strategy is to negotiate for a larger share of downstream success through royalties and milestones. This can yield far greater long-term returns if the product succeeds.

Even though companies like Moderna (mRNA) and Transgene (viral vector) use different platforms, positive results from any of them help validate the entire individualized neoantigen approach for investors and clinicians. The massive unmet medical need ensures the market is large enough to support multiple successful players.

Moderna spent $1 billion on a trial based on FDA guidance that was later deemed unacceptable. This arbitrary "changing of the rules" after the fact makes long-term, capital-intensive investment in new medicines like vaccines extremely risky for pharmaceutical companies.

The FDA's "refuse to file" decision is highly unusual, occurring in only 4% of cases and typically for incomplete or flawed applications. Using it to block Moderna's submission over a previously-agreed-upon trial comparator suggests a strategic shift in regulatory posture, not a simple procedural issue.

The acquisition of Verona shows that a novel mechanism of action with a substantial clinical effect can make a company a prime M&A target. This holds true even with weaknesses like no composition of matter patent or an unfashionable drug delivery method, especially in disease areas lacking innovation.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.

The current biotech M&A boom is less about frantically plugging near-term patent cliff gaps (e.g., 2026-2027) and more about building long-term, strategic franchises. This forward-looking approach allows big pharma to acquire earlier-stage platforms and assets, signaling a healthier, more sustainable M&A environment.